Search Results for: LCK

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CD38 CD38 molecule
  • Nicotinate metabolism
  • Daratumumab
  • Isatuximab
  • Mezagitamab
CD3E CD3e molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PD-1 signaling
  • Muromonab
  • Catumaxomab
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
CD4 CD4 molecule
  • Alpha-defensins
  • Nef Mediated CD4 Down-regulation
  • Binding and entry of HIV virion
  • Vpu mediated degradation of CD4
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PD-1 signaling
  • Other interleukin signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Antithymocyte immunoglobulin (rabbit)
  • Clenoliximab
  • Ibalizumab
CD44 CD44 molecule (Indian blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Hyaluronan uptake and degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
CD48 CD48 molecule
  • Cell surface interactions at the vascular wall
CD5 CD5 molecule
CD55 CD55 molecule (Cromer blood group)
  • Class B/2 (Secretin family receptors)
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • Regulation of Complement cascade
  • Chloramphenicol
  • Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
CD79A CD79a molecule
  • CD22 mediated BCR regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CD79B CD79b molecule
  • CD22 mediated BCR regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Polatuzumab vedotin
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CD8A CD8a molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
CDC25C cell division cycle 25C
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • RHO GTPases activate PKNs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDC42 cell division cycle 42
  • GPVI-mediated activation cascade
  • EGFR downregulation
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • G beta:gamma signalling through CDC42
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Aminophosphonic acid-guanylate ester
  • Guanosine-5'-Diphosphate
CDC45 cell division cycle 45
  • Activation of ATR in response to replication stress
  • Unwinding of DNA
  • Activation of the pre-replicative complex
  • G1/S-Specific Transcription
CDKAL1 CDK5 regulatory subunit associated protein 1 like 1
  • tRNA modification in the nucleus and cytosol
  • Type II diabetes mellitus
CSF2RB colony stimulating factor 2 receptor subunit beta
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • Surfactant metabolism
  • Defective CSF2RB causes SMDP5
  • Defective CSF2RA causes SMDP4
  • Interleukin receptor SHC signaling
  • Sargramostim
  • NPI 32101
  • Resatorvid
CSF3R colony stimulating factor 3 receptor
  • Other interleukin signaling
  • Transcriptional regulation of granulopoiesis
  • Pegfilgrastim
  • Filgrastim
  • FavId
  • Lenograstim
  • Lipegfilgrastim
CSK C-terminal Src kinase
  • GAB1 signalosome
  • Phosphorylation of CD3 and TCR zeta chains
  • Integrin signaling
  • PD-1 signaling
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Negative regulation of FLT3
  • Dasatinib
  • Staurosporine
  • TG-100801
  • Fostamatinib
CSNK2B casein kinase 2 beta
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • ATP
  • Quercetin
CTDSP1 CTD small phosphatase 1
  • Aspartate beryllium trifluoride
  • Citric acid
CTLA4 cytotoxic T-lymphocyte associated protein 4
  • CTLA4 inhibitory signaling
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Ipilimumab
  • Tremelimumab
  • Type I diabetes mellitus
  • Graves' disease
  • Allograft rejection
  • Hashimoto's thyroiditis

Page 2 out of 8 pages